nanotechnolog
fastgrow
field
provid
develop
materi
new
dimens
novel
properti
broader
array
applic
us
nation
nanotechnolog
initi
defin
nanoparticl
np
rang
nm
nation
nanotechnolog
initi
microbi
fungal
viral
infect
repres
increas
worldwid
threat
caus
gener
immunosuppress
world
popul
growth
resist
pathogen
clinic
use
drug
well
develop
crossresist
multidrugresist
strain
particular
virus
caus
number
diseas
worldwid
mani
fatal
termin
although
smallpox
erad
vaccin
develop
virus
continu
indic
us
convent
antivir
drugsstrategi
directli
target
viral
cellular
protein
limit
due
frequent
viru
variat
result
drug
resist
mani
drug
show
high
specif
eg
de
clercq
li
takizawa
yamasaki
wang
et
al
deng
wang
state
design
discoveri
structur
new
antiinfect
newinnov
mode
action
time
consum
rel
riski
b
moreov
mani
exist
antivir
demonstr
also
human
toxic
rapid
clearanc
bodi
thu
design
develop
new
safe
potent
antivir
activ
viral
infect
multipl
point
viral
life
cycl
remain
major
challeng
alghananeem
et
al
li
et
al
ko
et
al
strategi
base
reformul
exist
antiinfect
nanoformul
well
investig
variou
metal
metalloid
nanoparticl
respect
antiinfecti
activ
potenc
appli
frequent
et
al
fact
strategi
use
antiinfecti
drug
nanoformul
also
wide
use
differ
class
drug
antineoplast
pentak
et
al
antipsychot
antidepress
c
nootrop
et
al
nanoscal
dimens
significantli
modifi
properti
behavior
materi
eg
dolez
wherebi
benefit
pharmaceut
medic
nanoformul
belong
primarili
sustain
releas
drug
modif
bioavail
reduct
requir
drug
amount
reduct
toxic
drug
well
increas
drug
stabil
eg
patra
et
al
thu
light
mention
fact
nanomateri
constitut
use
tool
combat
virus
well
szunerit
et
al
milovanov
et
al
siddiq
et
al
singh
et
al
zazo
et
al
recent
find
relat
develop
virusbas
nanoparticl
np
system
vaccin
estim
prevent
treatment
infecti
diseas
chronic
diseas
cancer
addict
summar
lee
et
al
jackman
et
al
focus
attent
progress
applic
nanomedicin
strategi
control
critic
stage
viru
life
cycl
either
direct
indirect
approach
involv
membran
interfac
exampl
diagnost
prophylact
therapeut
applic
metal
metal
oxid
np
human
immunodefici
viru
hiv
hepat
viru
influenza
viru
herp
simplex
viru
hsv
infect
overview
yadav
shukla
scherliess
antivir
activ
metal
np
especi
mechan
action
agnp
differ
virus
hsv
hiv
hepat
b
viru
hbv
metapneumoviru
respiratori
syncyti
viru
rsv
discuss
rai
et
al
nonvir
gene
therapi
use
multifunct
np
eg
lipidbas
np
quantum
dot
carbon
nanotub
magnet
np
silica
np
polymerbas
np
advantag
nonvir
vector
ensur
enhanc
gene
stabil
gene
deliveri
shield
cargo
nucleas
degrad
improv
passiveact
target
lin
et
al
arizasaenz
et
al
entri
process
virus
host
cell
multival
interact
differ
cell
surfac
receptor
occur
mani
human
virus
attach
cell
heparan
sulfat
hs
proteoglycan
attach
viru
hs
cell
surfac
start
cascad
event
end
viru
entri
cagno
et
al
design
antivir
np
long
flexibl
linker
mimick
hs
proteoglycan
allow
effect
viral
associ
bind
simul
strong
multival
viral
attach
ligand
repeat
unit
gener
forc
eventu
lead
irrevers
viral
deform
show
nanomolar
irrevers
activ
hsv
human
papilloma
viru
rsv
dengu
viru
lentiviru
vitro
activ
ex
vivo
human
cervicovagin
histocultur
infect
vivo
mice
infect
rsv
nanogel
differ
degre
flexibl
base
dendrit
polyglycerol
sulfat
mimic
cellular
hs
design
dey
et
al
abl
multival
interact
viral
glycoprotein
shield
viru
surfac
effici
block
infect
found
act
robust
inhibitor
human
virus
dendrit
cell
crucial
develop
cellspecif
respons
bacteri
viral
pathogen
surfact
protein
form
import
part
innat
immun
respons
lung
interact
np
modul
cellular
uptak
particl
unmodifi
polystyren
np
nm
found
modul
surfact
protein
mediat
protect
influenza
infect
vitro
mckenzi
et
al
substitut
sulfat
group
cellulos
nanocryst
tyrosin
sulfat
mimet
group
ie
phenyl
sulfon
led
improv
viral
inhibit
indic
conjug
targetspecif
function
cellulos
nanocryst
surfac
provid
mean
control
antivir
activ
zopp
et
al
welldefin
structur
viru
due
multifunct
proteinac
shell
capsid
surround
genom
materi
promis
approach
obtain
nanostructur
materi
virus
exhibit
ideal
templat
format
nanoconjug
nobl
metal
np
interact
multifunct
virus
np
function
addit
result
gener
bioconjug
differ
properti
includ
possibl
antivir
antibacteri
activ
parboos
et
al
capek
contribut
focus
nanoscal
materialsformul
potenti
use
treat
inhibit
spread
viral
diseas
caus
human
immunodefici
viru
influenza
virus
subtyp
avian
influenza
swine
influenza
virus
respiratori
syncyti
viru
herp
simplex
viru
hepat
b
c
virus
ebola
marburg
virus
newcastl
diseas
viru
dengu
zika
virus
pseudorabi
viru
see
fig
effect
antivir
longlast
targetselect
nanoformul
develop
oral
intraven
intramuscular
intranas
intrarect
intravagin
intraderm
applic
discuss
benefit
nanoparticl
base
vaccin
nanoformul
potenti
secur
cross
protect
diverg
virus
outlin
well
human
immunodefici
viru
hiv
lentiviru
subgroup
retroviru
caus
hiv
infect
time
acquir
immunodefici
syndrom
aid
hiv
viru
spread
certain
bodi
fluid
kill
impair
cell
immun
system
specif
cell
progress
destroy
bodi
abil
fight
infect
certain
cancer
german
advisori
committe
blood
base
investig
antiretrovir
arv
activ
carbon
nanotub
cnt
use
comput
molecular
approach
strong
molecular
interact
suggest
efficaci
cnt
target
hivmedi
retrovir
infect
krishnaraj
et
al
also
highli
hydrophil
dispers
carboxyl
multiwal
carbon
nanotub
mwcnt
bear
arv
drug
hydrophil
function
found
exhibit
antihiv
activ
iannazzo
et
al
sinp
nm
prepar
grind
porou
silicon
found
act
effici
scaveng
hiv
rsv
osminkina
et
al
product
agnp
use
antivir
therapeut
pathogen
virus
review
galdiero
et
al
ag
nanocomplex
anion
linear
globular
dendrim
assess
hiv
replic
pathway
vitro
show
also
good
arv
activ
nonsever
toxic
effect
comparison
nevirapin
standard
drug
posit
control
group
ardestani
et
al
polyvinylpyrrolidon
pvp
coat
agnp
found
promis
microbicid
candid
use
topic
vaginalcerv
agent
prevent
transmiss
lara
et
al
inactiv
microbi
infecti
agnpscoat
condom
new
approach
inhibit
hiv
hsvtransmit
infect
propos
fayaz
et
al
treatment
infect
cell
curcuminstabil
agnp
nm
reduc
replic
hiv
inhibit
nfb
nuclear
transloc
downstream
express
proinflammatori
cytokin
tumor
necrosi
estim
similar
biolog
effect
observ
curcumin
alon
convent
agnp
cap
citric
acid
sharma
et
al
stabl
crystallin
agnp
fabric
use
aqueou
leaf
extract
mangrov
rhizophora
lamarckii
particl
size
rang
nm
inhibit
hiv
type
revers
transcriptas
activ
show
promis
potenti
use
fight
hiv
virus
public
health
import
kumar
et
al
aunp
cap
sulfateend
ligand
abl
bind
hiv
envelop
glycoprotein
inhibit
vitro
hiv
infect
cell
nanomolar
concentr
report
di
gianvincenzo
et
al
aunp
inhibit
hiv
entri
bind
prevent
attach
describ
vijayakumar
ganesan
peptid
load
onto
aunp
bear
highmannosidetyp
oligosaccharid
increas
hivspecif
cell
prolifer
induc
highli
function
cytokin
secret
compar
hiv
peptid
alon
elicit
highli
effici
secret
cytokin
chemokin
moder
product
consider
higher
secret
proinflammatori
cytokin
tumor
necrosi
suggest
aunp
could
simultan
deliv
antigen
highmannosidetyp
oligosaccharid
could
util
superb
vaccin
deliveri
system
climent
et
al
nowacek
et
al
perform
analys
nanoformul
arv
drug
found
physic
characterist
particl
size
surfact
coat
surfac
charg
importantli
shape
predictor
cell
uptak
arv
efficaci
progress
develop
npbase
drug
deliveri
system
hiv
therapi
focus
mainli
inject
nanocarri
enabl
deliveri
drug
combin
longlast
targetselect
physiolog
context
vivo
provid
safe
effect
use
summar
gao
et
al
exampl
tenofovir
tfv
alafenamid
elvitegravir
evg
load
np
subcutan
administ
femal
human
mice
show
long
resid
time
exposur
drug
auc
day
estim
tfv
evg
use
np
hml
applic
drug
solut
observ
auc
h
reach
hml
respect
similarli
applic
np
result
strong
increas
elimin
halflif
day
tfv
evg
respect
correspond
valu
free
drug
h
prathipati
et
al
jiang
et
al
incorpor
arv
drug
maraviroc
etravirin
raltegravir
poli
lacticcoglycol
acid
plga
np
found
arv
np
maintain
potent
hiv
inhibit
effect
use
combin
significantli
higher
antivir
potenc
dosedepend
reduct
cellfre
cellassoci
bal
infect
vitro
estim
mainli
arv
np
combin
involv
etravirin
np
wherebi
combin
show
larg
dosereduct
identifi
synergist
moreov
arv
np
combin
inhibit
propag
revers
transcriptas
simianhuman
immunodefici
virus
macaqu
cervicovagin
tissu
block
viru
transmiss
migratori
cell
emigr
tissu
pgla
np
also
use
biodegrad
carrier
load
tfv
combin
efavirenz
saquinavir
result
pronounc
combin
drug
effect
emphas
potenti
np
realiz
uniqu
drugdrug
activ
chaowanachan
et
al
tfv
evgload
plga
np
test
use
human
blt
mous
model
report
suitabl
longact
prevent
vagin
transmiss
mandal
et
al
vitro
inhibit
studi
valu
observ
emtricitabineload
plga
np
size
nm
surfac
charg
mv
found
lower
tzmbl
cell
approx
fourfold
lower
peripher
blood
mononuclear
cell
compar
drug
solut
respect
show
compar
activ
emtricitabin
solut
base
prolong
intracellular
drug
concentr
inhibit
hiv
infect
research
note
longact
stabl
formul
could
ensur
oncebiweekli
dose
prevent
treat
hiv
infect
mandal
et
al
plgaevg
np
nm
zeta
potenti
approx
mv
show
time
concentrationdepend
uptak
monocyt
approx
twofold
higher
drug
intracellular
intern
evg
compar
free
drug
also
exhibit
superior
viral
suppress
control
prolong
period
time
gong
et
al
due
presenc
mannos
receptor
surfac
macrophag
mannosyl
np
antihiv
drug
target
macrophag
result
improv
therapeut
outcom
reduc
toxic
arv
bioactiv
surfacefunction
mannosylatedplga
np
lamivudin
lvd
administ
intraven
rout
dose
mgkg
rat
show
pronouncedli
higher
calcul
brainplasma
ratio
plga
np
continu
increas
drug
concentr
h
patel
et
al
efvload
plga
np
prepar
use
microfluid
method
particl
size
nm
zeta
potenti
mv
drug
load
show
sustain
vitro
efv
releas
releas
within
first
h
np
function
transferrin
receptorbind
peptid
found
safe
blood
brain
barrier
bbb
endotheli
neuron
cell
metabol
activ
nonhemolyt
wherebi
function
nanosystem
exhibit
higher
drug
permeabl
bbb
vitro
model
compar
free
drug
martin
et
al
efvload
plga
np
plga
np
polyethylen
glycol
peg
coat
particl
size
nm
also
retain
nativ
arv
activ
drug
vitro
show
lower
cytotox
differ
epitheli
cell
line
hiv
target
cell
type
np
readili
taken
colorect
cell
line
mildli
reduc
efv
permeat
increas
membran
retent
cell
model
monolay
vitro
intrarect
administr
mice
phosphatebuff
salin
ph
coat
plga
np
encapsul
efv
reach
higher
drug
level
colorect
tissu
lavag
compar
free
efv
efvload
plga
np
provid
enhanc
local
pharmacokinet
could
benefici
prevent
rectal
hiv
transmiss
nune
et
al
tfv
efvload
plga
np
incorpor
alongsid
free
tfv
fast
dissolv
film
film
manufactur
show
higher
retent
vivo
vagin
lavag
tissu
associ
film
npsinfilm
still
abl
enhanc
drug
concentr
efv
film
alon
also
contribut
higher
prolong
local
drug
level
compar
administr
tfv
efv
aqueou
vehicl
daili
vagin
administr
mice
formul
caus
notabl
histolog
chang
major
alter
cytokinechemokin
profil
cunharei
et
al
comparison
evgload
nonadhes
surfacemodifi
bioadhes
poli
lactic
acid
hyperbranch
polyglycerol
np
formul
intravagin
administr
show
bioadhes
np
markedli
improv
prolong
intravagin
deliveri
drug
could
provid
sustain
protect
longer
durat
mohideen
et
al
atriplatrimethyl
chitosan
cs
np
nanoconjug
particl
size
nm
zeta
potenti
mv
show
higher
inhibitori
effect
hiv
replic
atripla
alon
low
dose
could
use
antivir
treatment
result
reduct
drug
resist
side
effect
shohani
et
al
spheric
intranas
efv
np
prepar
use
nm
drug
load
entrap
effici
ee
exhibit
sustain
drug
releas
h
greater
permeabl
porcin
nasal
mucosa
plain
drug
solut
higher
central
nervou
system
bioavail
drug
solut
administ
iv
rout
belgamwar
et
al
experi
np
coat
glycol
chitosan
load
inhibitor
peptid
test
vitro
ex
vivo
use
porcin
vagin
mucosa
show
formul
reach
vagin
tissu
releas
peptid
within
intercellular
space
without
side
effect
arizasaenz
et
al
novel
npinmicroparticl
mp
deliveri
system
nimd
compris
pure
np
darunavir
drv
boost
agent
ritonavir
rtv
encapsul
within
filmcoat
mp
report
pure
np
encapsul
within
calcium
alginatec
mp
filmcoat
seri
poli
methacryl
copolym
show
differenti
solubl
gastrointestin
tract
enabl
stabil
gastriclik
ph
sustain
drug
releas
intestin
one
use
formul
higher
oral
bioavail
drv
respect
unprocess
nanon
drvrtv
combin
estim
albino
spraguedawley
rat
augustin
et
al
enhanc
bioavail
darunavirload
lipid
nanoemuls
brain
oral
administr
describ
desai
thakkar
among
tfvload
target
mannos
respons
particl
prepar
layerbylay
coat
concanavalin
con
glycogen
one
con
layer
contain
system
show
twofold
increas
drug
releas
vs
control
concentr
hiv
percent
mucoadhes
estim
ex
vivo
porcin
vagin
tissu
rang
depend
number
con
layer
formul
coulibali
et
al
hillaireau
et
al
refer
potenti
nanoassembl
nucleosid
revers
transcriptas
inhibitor
nrti
deliv
squalenoyl
prodrug
enhanc
absorpt
improv
biodistribut
also
enhanc
intracellular
deliveri
antivir
efficaci
toward
hivinfect
cell
biodegrad
cation
nanogel
carrier
deliveri
triphosphoryl
nrti
demonstr
high
antihiv
activ
along
low
neurotox
warrant
minim
side
effect
follow
system
administr
prepar
warren
et
al
nanogel
modif
brainspecif
peptid
vector
result
effici
central
nervou
system
target
senanayak
et
al
conjug
succin
deriv
nrti
nanogel
nanogel
conjug
zidovudin
zdv
lvd
abacavir
demonstr
tenfold
suppress
revers
transcriptas
activ
hivinfect
macrophag
drug
level
respect
singl
nanodrug
dual
tripl
nanodrug
cocktail
conjug
lvd
effect
singl
nanodrug
np
nm
prepar
encapsul
zdv
lactoferrin
np
found
stabl
simul
gastric
intestin
fluid
activ
drug
remain
unalt
nanoformul
acut
infect
drug
releas
np
constant
h
bone
marrow
micronucleu
assay
show
nanoformul
exhibit
ca
twofold
lower
toxic
solubl
form
kumar
et
al
lactoferrin
np
load
tripl
drug
combin
zdv
efv
lvd
show
diamet
nm
ee
drug
deliv
maximum
payload
ph
minimum
burst
releas
vitro
exhibit
improv
antihiv
activ
practic
toxic
erythrocyt
reach
vivo
experi
approx
increas
auc
increas
cmax
compar
individu
drug
enhanc
halflif
drug
also
show
improv
bioavail
drug
less
tissuerel
inflamm
kumar
et
al
improv
hivmicrobicid
activ
coencapsul
drug
act
nrti
biocompat
metal
organ
framework
nanocarri
contain
iron
iii
polycarboxyl
np
report
marcosalmaraz
et
al
tfv
disoproxil
fumar
encapsul
multifunct
magnetoplasmon
liposom
hybrid
system
combin
liposom
magnetoplasmon
np
enabl
treatment
brain
microenviron
inaccess
drug
show
enhanc
transmigr
across
vitro
bbb
model
magnet
target
exhibit
desir
therapeut
effect
hivinfect
microglia
cell
gold
shell
liposom
show
bright
posit
contrast
xray
comput
tomographi
tomitaka
et
al
efvload
solid
lipid
np
slnp
mean
particl
size
nm
polydispers
index
ee
administ
intranas
vivo
reveal
increas
concentr
drug
brain
desir
suggest
potenti
use
erad
hiv
cure
hivinfect
patient
gupta
et
al
endsley
ho
construct
slnp
provid
select
bind
effici
deliveri
indinavir
host
cell
wherebi
inclus
peg
slnp
minim
immun
recognit
peptid
show
enhanc
antihiv
effect
even
limit
time
exposur
nanosc
nrti
decor
peptidebind
brainspecif
apolipoprotein
e
receptor
demonstr
low
neurotox
high
antivir
activ
hiv
infect
brain
gerson
et
al
cell
surfac
chemokin
receptor
target
peptid
act
hiv
entri
inhibitor
ligand
target
drug
deliveri
describ
lee
et
al
use
target
ligand
result
enhanc
endocytosi
due
uptak
function
nanocarri
combin
alloster
interact
suggest
peptid
could
consid
dual
function
ligand
bayon
et
al
develop
vaccin
formul
compris
nanostructur
lipid
carrier
nlc
graft
antigen
togeth
cation
nlc
optim
deliveri
immunostimul
cpg
abl
notabl
enhanc
immun
respons
manifest
specif
antibodi
product
cell
activ
mice
well
nonhuman
primat
tissu
celltarget
longact
fourinon
nanosuspens
compos
lopinavir
rtv
tfv
lvd
administ
singl
inject
subcutan
four
macaqu
abl
exhibit
persist
drug
level
lymph
node
mononuclear
cell
peripher
blood
mononuclear
cell
week
could
propos
longact
treatment
potenti
target
residu
viru
tissu
improv
patient
adher
mcconnachi
et
al
biocompat
zdvload
hybrid
coreshel
np
carboxymethyl
cellulos
core
shell
arv
drug
deliveri
mean
size
nm
drug
ee
show
control
drug
releas
abl
effect
enter
brain
cell
joshi
et
al
biocompat
np
amid
function
algin
prepar
coupl
reaction
lglutam
acid
encapsul
zdv
mean
size
nm
load
efficaci
show
slow
sustain
releas
drug
phosphatebuff
salin
pb
ph
exhibit
significantli
higher
cellular
intern
effici
vitro
joshi
et
al
consider
improv
cellular
intern
murin
hela
cell
vitro
observ
also
zdvload
pvpstearic
acid
sa
peg
np
due
coreshel
np
prepar
lipid
polym
suggest
np
potenti
use
antivir
drug
deliveri
use
hivaid
therapi
joshi
et
al
zdvload
coreshel
dextran
hybrid
nanosystem
express
enhanc
cellular
intern
drugload
hybrid
np
comparison
free
drug
joshi
et
al
retain
intracytoplasm
nanoformul
consist
hydrophob
lipophil
modifi
dolutegravir
prodrug
encapsul
poloxam
releas
drug
macrophag
suppress
viral
replic
spread
viru
cell
drug
blood
tissu
level
balbcj
mice
ngml
correspond
valu
day
respect
sillman
et
al
crystal
myristoyl
cabotegravir
prodrug
formul
np
facilit
avid
monocytemacrophag
entri
retent
reticuloendotheli
system
depot
formul
show
sustain
protect
challeng
singl
mgkg
intramuscular
inject
np
dose
mgkg
balbcj
mice
result
fourfold
higher
pharmacokinet
profil
compar
longact
parenter
cabotegravir
similar
result
obtain
also
rhesu
macaqu
macaca
mulatta
improv
viral
restrict
human
adult
lymphocytereconstitut
mice
nanoformul
observ
well
zhou
et
al
influenza
respiratori
ill
caus
viru
influenza
virus
negativesens
singlestrand
segment
rna
virus
virus
influenza
type
occur
human
anim
type
b
c
found
human
influenza
virus
classifi
accord
type
hemagglutinin
h
type
neuroaminidas
n
subtyp
viru
subtyp
mutat
varieti
strain
differ
pathogen
profil
use
human
blt
mous
model
taubenberg
moren
takizawa
yamasaki
influenza
viru
caus
influenza
bird
mammal
speci
alphainfluenzaviru
genu
orthomyxovirida
famili
virus
type
influenza
contagi
viral
infect
lifethreaten
complic
left
untreat
influenza
could
pandem
epidem
influenza
viru
spread
worldwid
scale
eg
spanish
flu
kuchipudi
niessli
inhibit
influenza
viru
infect
agnp
vitro
vivo
report
xiang
et
al
feng
et
al
design
glycosyl
metal
ag
au
np
potent
influenza
viru
hemagglutinin
ha
blocker
inhibitori
effect
agnp
particl
size
nm
influenza
viru
vitro
also
report
xiang
et
al
effect
size
depend
agnp
nm
averag
diamet
embed
cs
matrix
antivir
activ
influenza
viru
also
observ
show
gener
stronger
antivir
activ
smaller
agnp
composit
mori
et
al
evalu
efficaci
agnpdecor
silica
hybrid
composit
particl
size
nm
diamet
inactiv
influenza
viru
show
even
h
exposur
np
ha
damag
neuraminidas
activ
reduct
infect
caus
viru
madindarbi
canin
kidney
mdck
cell
observ
np
found
interact
viral
compon
situat
membran
caus
nonspecif
damag
result
viru
inactiv
park
et
al
primari
mechan
influenza
viru
inhibit
aunp
differ
anion
group
block
viral
attach
cell
surfac
suggest
although
viral
fusion
inhibit
could
exclud
sametband
et
al
li
et
al
propos
new
modal
inhibit
viral
infect
fabric
dnaconjug
aunp
network
cell
membran
protect
barrier
antivir
activ
may
attribut
steric
effect
disrupt
membran
glycoprotein
limit
fusion
cell
membran
bilay
addit
dnaaunp
besid
inhibit
viru
attach
entri
could
also
inhibit
viral
bud
celltocel
spread
multival
sialic
acidfunction
aunp
nm
inhibit
influenza
viru
infect
bind
viral
fusion
protein
ha
host
cell
surfac
mediat
sialic
acid
receptor
multival
interact
sialic
acidfunction
aunp
expect
competit
inhibit
viral
infect
papp
et
al
intranas
immun
mixtur
conjug
recombin
trimetr
influenza
ha
onto
function
aunp
surfac
repetit
orient
configur
aunp
coupl
tolllik
receptor
agonist
flagellin
particul
adjuv
result
improv
mucos
b
cell
respons
increas
influenzaspecif
immunoglobulin
ig
igg
l
nasal
tracheal
lung
wash
stimul
antigenspecif
cell
prolifer
induc
strong
effector
cell
activ
suggest
power
mucos
system
immun
respons
protect
host
lethal
influenza
challeng
wang
et
al
cui
np
mean
size
nm
exert
antivir
activ
influenza
viru
swine
origin
pandem
gener
hydroxyl
radic
suggest
could
appli
filter
face
mask
protect
cloth
kitchen
cloth
materi
suitabl
protect
viral
attack
fujimori
et
al
nanocomposit
dna
fragment
electrostat
bound
np
precov
polylysin
effici
inhibit
human
influenza
subtyp
levina
et
al
composit
peptid
nucleic
acid
npcontain
dnapeptid
nucleic
acid
duplex
inhibit
reproduct
influenza
viru
subtyp
effici
shown
penetr
cell
membran
also
exhibit
high
specif
antisens
activ
without
toxic
effect
live
cell
amirkhanov
et
al
senp
decor
ribavirin
rbv
broadspectrum
antivir
drug
protect
cell
infect
vitro
vivo
experi
prevent
lung
injuri
mice
significantli
reduc
dna
damag
lung
tissu
restrain
activ
protein
apoptosi
pathway
lin
et
al
pieler
et
al
bound
inactiv
concentr
diafilt
influenza
viru
particl
produc
mdck
cell
suspens
magnet
sulfat
cellulos
microparticl
directli
inject
mice
immun
observ
high
antiinfluenza
antibodi
respons
full
protect
lethal
challeng
replicationcompet
influenza
viru
wherebi
reduc
number
influenza
nucleoprotein
gene
copi
lung
mice
immun
antigenload
microparticl
compar
mocktreat
anim
estim
hybrid
inorganicorgan
microcapsul
obtain
encapsul
sirna
via
combin
layerbylay
techniqu
situ
modif
solgel
chemistri
character
high
cell
uptak
effici
low
toxic
effici
intracellular
deliveri
sirna
protect
sirna
prematur
degrad
reach
target
cell
reduc
viral
nucleoprotein
level
inhibit
influenza
viru
product
infect
mdck
cell
timin
et
al
cs
np
load
sirna
effici
uptaken
vero
cell
result
inhibit
influenza
viru
strain
replic
vitro
show
antivir
effect
nasal
administr
consider
protect
balbc
mice
lethal
influenza
challeng
suggest
nanoformul
promis
system
control
influenza
viru
infect
jamali
et
al
figueira
et
al
modifi
influenza
fusion
inhibitor
ad
cellpenetr
peptid
selfassembl
nm
np
target
relev
tissu
infect
influenza
viru
vivo
caus
reduct
viral
infect
upon
interact
cell
membran
shown
efficaci
biodistribut
fusion
inhibit
efficaci
vivo
cellpenetr
peptid
lipid
moieti
necessari
amino
acid
sequenc
influenza
matrix
protein
ectodomain
highli
conserv
among
human
season
influenza
virus
deng
et
al
multival
oleanol
acid
protein
conjug
nonglycosyl
neomucin
mimic
captur
entri
inhibit
influenza
virus
design
yang
et
al
found
compar
natur
glycosyl
mucin
suggest
materi
could
potenti
use
antiinfect
barrier
prevent
viru
invad
host
cell
bernasconi
et
al
develop
fusion
protein
three
copi
ectodomain
matrix
protein
one
explor
conserv
influenza
viru
antigen
broadli
protect
vaccin
incorpor
porou
maltodextrin
np
enhanc
protect
abil
formul
result
broadli
protect
immun
lethal
infect
heterosubtyp
influenza
viru
immun
protect
mediat
enhanc
level
lungresid
cell
well
antiha
serum
igg
local
iga
antibodi
initi
adhes
virus
quantit
control
multival
bind
protein
glycan
receptor
host
cell
lin
et
al
mimic
viru
adhes
cell
surfac
attach
proteinoligomerco
np
fluidic
glycolipid
membran
surfac
glycan
densiti
vari
four
order
magnitud
found
bind
isotherm
two
region
could
estim
could
attribut
monoval
multival
proteinglycan
interact
low
high
glycan
densiti
respect
lauster
et
al
design
multival
peptidepolym
np
consist
coval
conjug
peptid
ligand
biocompat
polyglycerolbas
hydrophil
dendrit
scaffold
show
bind
nanomolar
affin
influenza
viru
via
spike
protein
hemagglutinin
novel
season
recombin
ha
np
influenza
vaccin
niv
formul
saponinbas
adjuv
induc
ha
inhibit
hai
microneutr
antibodi
broad
rang
influenza
subtyp
haiposit
haineg
neutral
monoclon
antibodi
deriv
mice
immun
niv
activ
homolog
drift
influenza
strain
smith
et
al
layer
protein
np
compos
structurestabil
ha
stalk
domain
ha
group
construct
report
potenti
develop
univers
influenza
vaccin
could
induc
broad
cross
protect
diverg
virus
deng
et
al
intranas
administ
biocompat
polyanhydrid
npbase
influenza
viru
iav
vaccin
iavnanovax
could
provid
protect
subsequ
homolog
heterolog
iav
infect
inbr
outbr
popul
use
vaccin
result
promot
induct
germin
center
b
cell
within
lung
system
lung
local
iavspecif
antibodi
iavspecif
lungresid
memori
cell
zacharia
et
al
doublelay
peptid
np
prepar
desolv
composit
peptid
tandem
copi
nucleoprotein
epitop
np
core
crosslink
anoth
composit
peptid
four
tandem
copi
influenza
matrix
protein
ectodomain
epitop
core
surfac
coat
deliv
via
dissolv
microneedl
patchbas
skin
vaccin
induc
robust
specif
immun
protect
mice
heterosubtyp
influenza
viru
challeng
demonstr
strong
antigen
depot
effect
result
stronger
immun
respons
wherebi
cell
involv
protect
deng
et
al
intranas
vaccin
np
form
repeat
selfassembl
recombin
human
heavi
chain
ferritin
cage
could
induc
robust
immun
respons
high
titer
sera
igg
antibodi
cell
immun
respons
mucos
secretori
iga
antibodi
mice
absenc
adjuv
np
also
confer
complet
protect
lethal
infect
homosubtyp
heterosubtyp
viru
could
consid
promis
needlefre
intranas
administ
crossprotect
influenza
vaccin
econom
suitabl
largescal
product
qi
et
al
avian
influenza
varieti
influenza
caus
virus
adapt
bird
avian
influenza
viru
aiv
atyp
influenza
viru
belong
orthomyxovirida
famili
wherebi
isol
strain
highli
pathogen
avian
influenza
induc
intraven
pathogen
index
mortal
rate
defin
chicken
popul
specifi
interv
day
subtyp
chatziprodromid
et
al
swine
influenza
caus
swine
influenza
virus
swiv
endem
pig
europ
swine
influenza
consid
one
import
primari
pathogen
swine
respiratori
diseas
infect
primarili
influenza
virus
brown
found
dietari
supplement
chromium
picolin
ppb
chromium
np
ppb
improv
perform
antibodi
titer
avian
influenza
infecti
bronchiti
heat
stress
condit
broiler
hajializadeh
et
al
serum
sampl
collect
immun
chicken
formul
consist
plasmid
encod
ha
gene
aiv
formul
use
biosynthes
agnp
nm
peg
show
rapidli
increas
antibodi
respons
day
immun
singl
oral
administr
formul
result
induct
antibodi
cellmedi
immun
respons
well
enhanc
cytokin
product
jazayeri
et
al
vaccin
formul
consist
ion
channel
membran
matrix
protein
extracellular
domain
influenza
conjug
aunp
cpg
oligodeoxynucleotid
solubl
adjuv
deliv
intranas
mice
result
lung
b
cell
activ
robust
serum
igg
respons
stimul
subtyp
lethal
challeng
vaccin
mice
pandem
strain
highli
pathogen
aiv
result
protect
tao
et
al
consid
import
role
mucos
immun
antivir
immun
respons
agnp
biofabr
use
cinnamomum
cassia
extract
show
enhanc
antivir
activ
highli
pathogen
aiv
subtyp
incub
viru
prior
infect
well
introduc
cell
infect
wherebi
test
concentr
extract
agnp
found
nontox
vero
cell
fatima
et
al
complex
necessari
mention
discuss
fujimori
et
al
describ
antivir
activ
cui
np
influenza
viru
swine
origin
formul
use
calcium
phosphat
np
vaccin
adjuv
deliveri
platform
formul
inactiv
whole
viru
pandem
influenza
vaccin
potenti
dosespar
strategi
intramuscularli
administ
balic
mice
dose
base
ha
content
result
higher
hai
viru
neutral
igg
antibodi
titer
compar
nonadjuv
vaccin
provid
equal
protect
onethird
antigen
dose
compar
nonadjuv
alum
hydrat
doubl
sulfat
salt
aluminum
potassium
sodium
ammonium
adjuv
vaccin
morcol
et
al
solut
nanoscal
scallop
shell
powder
produc
calcin
process
show
size
nm
inactiv
aiv
within
wherea
solut
greater
powder
particl
could
even
h
incub
moreov
inactiv
newcastl
diseas
viru
goos
parvoviru
solut
nanopowd
within
respect
observ
well
thammakarn
et
al
chicken
immun
low
dose
bioadhes
liposom
influenza
vaccin
use
liposom
prepar
tremella
xanthan
gum
bioadhes
polysaccharid
show
consider
higher
mucos
serum
antibodi
level
lowviscos
gel
mix
liposom
found
suitabl
nasal
deliveri
chicken
elicit
higher
mucos
secretori
iga
serum
igg
two
vaccin
compar
applic
liposom
mixtur
highviscos
gel
chiou
et
al
vaccin
chicken
nonencapsul
aiv
combin
plgaencapsul
cpg
oligodeoxynucleotid
cpg
result
qualit
quantit
augment
antibodi
respons
manifest
reduct
viru
shed
compar
encapsul
aiv
combin
plgaencapsul
cpg
formul
singh
et
al
similarli
nonencapsul
cpg
inactiv
aiv
vaccin
administ
intramuscular
rout
gener
higher
antibodi
respons
compar
cpg
encapsul
plga
plgaencapsul
cpg
aiv
vaccin
administ
aerosol
rout
elicit
higher
mucos
respons
compar
nonencapsul
cpg
singh
et
al
seok
et
al
design
intraderm
dna
vaccin
deliveri
platform
use
microneedl
coat
polyplexcontain
plgapolyethyleneimin
np
induc
greater
humor
immun
respons
due
rapid
dissolut
coat
polyplex
porcin
skin
within
min
observ
intramuscular
polyplex
deliveri
nake
dna
vaccin
deliveri
drycoat
microneedl
consequ
intraderm
deliveri
dna
vaccin
within
cation
polyplex
coat
microneedl
potenti
skin
immun
polyanhydrid
np
encapsul
subunit
protein
enhanc
humor
cellmedi
immun
provid
protect
upon
lethal
challeng
robust
immunogen
recombin
hemagglutinin
trimer
encapsul
polyanhydrid
np
use
immun
mice
induc
high
neutral
antibodi
titer
enhanc
cell
recal
respons
mice
polyanhydrid
nanovaccin
induc
protect
immun
lowpathogen
viral
challeng
ross
et
al
similarli
intranas
deliveri
nanovaccin
consist
inactiv
swiv
encapsul
polyanhydrid
np
enhanc
antigenspecif
cellular
immun
respons
pig
promis
induc
crossprotect
immun
dhakal
et
al
inactiv
swiv
encapsul
plga
np
nm
diamet
administ
via
intranas
rout
reduc
clinic
diseas
induc
crossprotect
cellmedi
immun
respons
pig
model
well
dhakal
et
al
viru
challeng
test
moon
et
al
use
hpai
viru
isol
fecal
specimen
collect
wild
bird
habitat
construct
recombin
ha
antigen
base
head
domain
viru
intranas
immun
mixtur
recombin
influenza
ha
antigen
inactiv
viru
acid
pga
cs
np
induc
high
antiha
iga
respons
lung
igg
respons
serum
includ
antiha
neutral
antibodi
well
influenza
virusspecif
cellmedi
immun
respons
femal
balbc
mice
challeng
lethal
dose
highli
pathogen
influenza
viru
moon
et
al
pig
intranas
vaccin
kill
swine
influenza
viru
antigen
encapsul
cs
polymerbas
np
exhibit
enhanc
igg
serum
antibodi
mucos
secretori
iga
antibodi
respons
nasal
swab
bronchoalveolar
lavag
fluid
lung
lysat
reactiv
homolog
heterolog
heterosubtyp
influenza
viru
strain
dhakal
et
al
mucos
vaccin
conserv
matrix
protein
fusion
peptid
hemagglutinin
cholera
toxin
subunit
al
ctai
fusion
protein
poli
np
induc
protect
diverg
influenza
subtyp
found
induc
high
degre
system
immun
igg
iga
site
inocul
challeng
test
balic
mice
sever
virus
provid
cross
protect
diverg
lethal
influenza
subtyp
month
vaccin
chowdhuri
et
al
two
immun
modifi
nonrepl
mrna
encod
influenza
hemagglutinin
encapsul
lipid
np
induc
protect
ha
inhibit
titer
cell
respons
intramuscular
intraderm
deliveri
rhesu
macaqu
liang
et
al
result
hemagglutin
inhibit
microneutr
assay
show
lipid
npformul
modifi
mrna
vaccin
encod
ha
protein
gener
rapid
robust
immun
respons
mice
ferret
nonhuman
primat
singl
dose
mrna
abl
protect
mice
lethal
challeng
reduc
lung
viral
titer
ferret
bahl
et
al
coat
twolay
protein
nanoclust
recombin
trimer
ha
avianorigin
influenza
evalu
virusspecif
immun
respons
protect
efficaci
mice
immun
nanoclust
found
highli
immunogen
abl
induc
protect
immun
longlast
humor
antibodi
respons
viru
without
use
adjuv
suggest
coat
nanoclust
also
great
potenti
influenza
vaccin
product
respons
emerg
pandem
also
replac
convent
season
influenza
vaccin
wang
et
al
respiratori
syncyti
viru
rsv
negativesens
singlestrand
envelop
rna
viru
global
human
pathogen
respons
lower
respiratori
tract
infect
consid
major
viral
pathogen
lower
respiratori
tract
infant
therefor
urgent
need
util
conveni
strategi
prevent
rsv
infect
includ
besid
live
attenu
chimer
subunit
vaccin
also
nanos
particl
borcher
et
al
clark
guerreroplata
au
nanorod
aunr
found
inhibit
rsv
human
epitheli
type
cell
balbc
mice
respect
wherebi
rsv
inhibit
correl
mark
upregul
antivir
gene
due
aunrmedi
tolllik
receptor
nucleotidebind
oligomer
domain
nod
like
receptor
retino
acidinduc
genei
rigi
like
receptor
signal
pathway
wherebi
recruit
immun
cell
counter
rsv
replic
demonstr
product
cytokin
chemokin
lung
bawag
et
al
treatment
human
dendrit
cell
aunr
conjug
rsv
f
formul
candid
vaccin
prepar
rsv
coval
attach
viral
protein
use
layerbylay
approach
induc
immun
respons
primari
human
cell
stone
et
al
curcuminmodifi
agnp
show
strong
inhibitori
activ
rsv
infect
result
reduct
viral
titer
two
order
magnitud
agnp
concentr
show
toxic
host
cell
wherebi
agnp
inactiv
viru
directli
result
prevent
rsv
infect
host
cell
yang
et
al
balbc
mice
expos
singl
dose
intranas
administ
np
mgkg
day
later
infect
intranas
rsv
notabl
increas
level
chemokin
bronchoalveolar
lavag
fluid
estim
compar
control
day
postinfect
uninfect
mice
exposur
result
also
increas
infiltr
lymphocyt
alveolar
septa
lung
tissu
pulmonari
viral
titer
affect
consequ
state
immun
system
affect
singl
exposur
np
exacerb
pneumonia
rsvinfect
mice
hashiguchi
et
al
curcuminload
graphen
oxid
go
composit
found
caus
highli
effici
inhibit
rsv
infect
show
great
biocompat
host
cell
abl
prevent
host
cell
rsv
infect
directli
inactiv
viru
inhibit
viral
attach
show
prophylact
therapeut
effect
toward
rsv
yang
et
al
recent
advanc
prophylact
synthet
biodegrad
microparticl
nanoparticl
vaccin
rsv
multipl
factor
affect
vaccin
efficaci
summar
jorquera
tripp
vaccin
recombin
rsv
f
nanoparticl
vaccin
g
rsv
f
protein
without
aluminum
phosphat
adjuv
enhanc
function
immun
rsv
older
adult
year
show
accept
safeti
profil
addit
immunogen
benefit
observ
adjuv
formul
compar
increas
antigen
dose
alon
moreov
rsv
f
vaccin
coadminist
licens
inactiv
trival
influenza
vaccin
tiv
impact
serum
hai
antibodi
respons
standarddos
tiv
tiv
affect
immun
respons
rsv
f
vaccin
fri
et
al
doublestrand
dna
virus
herp
simplex
viru
member
subfamili
herpesvirida
famili
infect
human
caus
cold
sore
caus
genit
herp
virus
establish
lifelong
latent
infect
within
peripher
nervou
system
dai
zhou
sizedepend
interact
agnp
human
parainfluenza
viru
type
result
reduc
viral
infect
inhibit
infect
virus
smallers
np
caus
probabl
block
interact
viru
cell
describ
gaikwad
et
al
agnp
appli
nontox
concentr
administ
prior
viral
infect
soon
initi
viru
exposur
capabl
inhibit
replic
suggest
agnp
act
earli
phase
viral
replic
hu
et
al
tannic
acidmodifi
agnp
nm
show
antivir
activ
reduc
infect
inflammatori
reaction
mous
model
infect
use
infect
postinfect
treatment
orlowski
et
al
antivir
activ
np
size
nm
appli
upon
mucos
tissu
caus
activ
immun
respons
vagin
orlowski
et
al
multifunct
tannic
acidagnpsbas
mucoadhes
hydrogel
effect
vagin
treatment
genit
infect
also
report
szymanska
et
al
investig
abil
tannic
acidmodifi
ag
au
np
induc
dendrit
cell
matur
activ
presenc
antigen
use
nontox
dose
show
type
metal
np
good
activ
dendrit
cell
albeit
final
effect
upon
matur
activ
may
metal
size
depend
help
overcom
virusinduc
suppress
dendrit
cell
activ
orlowski
et
al
aunp
size
nm
surfaceconjug
gallic
acid
show
antivir
efficaci
hsv
infect
vero
cell
haider
et
al
aunp
cap
mercaptoethanesulfon
me
strongli
inhibit
wherebi
interf
viral
attach
entri
celltocel
spread
therebi
prevent
subsequ
viral
infect
multimod
manner
barampinto
et
al
howev
antivir
effect
mescap
agnp
found
impart
multival
natur
spatial
direct
me
surfac
barampinto
et
al
overview
relat
applic
agnp
inhibit
hsv
present
akbarzadeh
et
al
zno
micronano
structur
cap
multipl
nanoscop
spike
mimick
cell
induc
filopodia
show
partial
neg
charg
oxygen
vacanc
nanoscop
spike
trap
virion
render
unabl
enter
human
corneal
natur
target
cell
infect
exhibit
pronouncedli
enhanc
effect
creat
addit
oxygen
vacanc
uv
light
illumin
mishra
et
al
intravagin
zno
tetrapod
np
engin
oxygen
vacanc
use
intravagin
act
microbicid
found
effect
suppressor
genit
infect
femal
balbc
mice
suppress
also
reinfect
exhibit
strong
adjuvantlik
properti
well
antoin
et
al
antivir
effect
zno
tetrapod
enhanc
illumin
uv
light
antoin
et
al
nanowir
work
carrier
neg
charg
structur
compet
attach
cellbound
hs
result
inhibit
viru
entri
subsequ
celltocel
spread
trigilio
et
al
acyclovir
acv
load
glycosaminoglycanmodifi
mesopor
np
reduc
viral
infect
hsv
np
abl
simultan
inhibit
viral
entri
dna
replic
lee
et
al
graphen
sheet
uniformli
anchor
spheric
sulfon
magnet
np
abl
captur
phototherm
destroy
upon
irradi
nearinfrar
light
nm
min
deokar
et
al
graphen
sheet
approx
nm
size
degre
sulfat
approx
found
oper
effect
viral
inhibitor
inhibit
hsv
infect
earli
stage
entri
affect
celltocel
spread
ziem
et
al
multival
flexibl
carbon
architectur
fabric
use
reduc
go
function
sulfat
dendrit
polyglycerol
mimic
hscontain
surfac
cell
compet
natur
bind
site
virus
demonstr
excel
bind
well
effici
inhibit
infect
orthopoxviru
possess
hsdepend
cell
entri
mechan
ziem
et
al
carbon
nanodot
surfacefunction
acid
hydrochlorid
prevent
infect
vero
cell
show
ngml
respect
specif
act
earli
stage
viru
entri
barra
et
al
cglycosylflavonoidenrich
fraction
cecropia
glaziovii
encapsul
plga
np
show
antiherp
properti
could
consid
promis
system
effect
drug
deliveri
treatment
herp
infect
do
santo
et
al
cymbopogon
citratu
volatil
oil
encapsul
plga
np
incorpor
carbom
hydrogel
test
hsv
use
vero
cell
inhibit
viru
lower
concentr
free
oil
effici
oilload
np
hydrogel
contain
free
oil
respect
almeida
et
al
genisteinload
cation
nanoemuls
averag
droplet
size
approx
nm
contain
hydroxyethyl
cellulos
thicken
agent
show
consider
reduc
genistein
flux
excis
porcin
mucosa
specimen
compar
nanoemuls
thicken
exhibit
notabl
increas
genistein
retent
mucosa
compar
genistein
propylen
glycol
solut
show
antiherpet
activ
vitro
strain
argenta
et
al
suspens
glycyrrhiz
acid
np
particl
size
approx
nm
exhibit
better
antihsv
activ
compar
glycyrrhiz
acid
ammonium
salt
especi
replic
period
morpholog
observ
transmiss
electron
microscopi
found
damag
shed
envelop
wang
et
al
antivir
activ
estim
use
cytopath
effect
assay
show
also
microemuls
mean
nanodroplet
diamet
nm
consist
oil
water
surfact
cosurfact
abl
destroy
viru
dilut
dulbecco
modifi
eagl
medium
alkhatib
et
al
pentyl
gallat
nanoemuls
particl
size
nm
zeta
potenti
rang
mv
demonstr
activ
drug
reach
deeper
dermi
effici
nanoemuls
free
drug
suggest
nanoemuls
potenti
use
topic
deliv
pentyl
gallat
treatment
human
herp
labiali
infect
affect
primarili
lip
kelmann
et
al
enhanc
antivir
activ
clinic
isol
determin
use
acvload
spheric
carboxyl
cyclodextrinbas
nanospong
carri
carboxyl
group
size
nm
exhibit
prolong
releas
comparison
observ
nanospong
without
initi
burst
effect
lembo
et
al
formul
acvload
flexibl
membran
vesicl
particl
size
zeta
potenti
nm
mv
respect
incorpor
hydrogel
enhanc
retent
drug
deep
insid
skin
layer
indic
potenti
reduc
need
applic
frequenc
result
reduc
advers
effect
suitabl
formul
topic
applic
infect
sharma
et
al
acv
entrap
nanostructur
lipid
carrier
coat
cs
increas
corneal
bioavail
albino
rabbit
compar
commerci
avail
ophthalm
ointment
drug
wherebi
nanoformul
show
sustain
releas
improv
antivir
properti
acv
cell
intern
seyfoddin
et
al
acvload
cs
np
show
spheric
shape
size
approx
nm
zeta
potenti
approx
mv
show
improv
vitro
skin
permeat
higher
antivir
activ
free
drug
strain
donalisio
et
al
cs
immunomodul
adjuv
cell
antigenpres
cell
infect
mice
report
choi
et
al
dendrit
cellbas
dna
vaccin
carri
cs
np
express
glycoprotein
formul
effect
target
corneal
dendrit
cell
significantli
allevi
symptom
primari
recurr
hsv
kerat
mice
via
elicit
strong
humor
cellular
immun
respons
suggest
vaccin
could
success
use
herp
simplex
kerat
treatment
tang
et
al
biomimet
supramolecular
hexagonalshap
nanoassembl
compos
chondroitin
sulfat
form
mix
hydrophob
modifi
chondroitin
sulfat
water
show
improv
antivir
activ
compar
hydrophob
modifi
chondroitin
sulfat
galu
et
al
acv
found
increasingli
permeat
multilay
human
corneal
epitheli
cell
drugload
bovin
serum
albumin
np
approx
nm
compar
drug
solut
suggest
potenti
formul
use
ocular
drug
deliveri
system
suwannoi
et
al
hepat
b
viru
hbv
speci
genu
orthohepadnaviru
member
hepadnavirida
famili
virus
doublestrand
dna
viru
replic
revers
transcript
hepat
c
viru
hcv
envelop
positivesens
singlestrand
rna
viru
famili
flavivirida
zuckerman
hbv
hbc
affect
liver
caus
acut
chronic
infect
wherebi
cirrhosi
liver
cancer
may
eventu
develop
viral
hepat
caus
million
death
number
compar
death
caus
tuberculosi
higher
caus
hiv
seventh
lead
caus
death
worldwid
stanaway
et
al
world
health
organ
presenc
hepat
b
viru
core
antigen
hbcag
major
structur
protein
hepat
b
viru
hbv
blood
serum
indic
person
expos
hbv
liang
inou
tanaka
lu
et
al
estim
agnp
size
nm
inhibit
vitro
product
hbv
rna
extracellular
virion
assum
direct
interact
np
hbv
doublestrand
dna
viral
particl
respons
antivir
mechan
lee
et
al
propos
hyaluron
complex
target
treatment
hcv
infect
antivir
effect
aunp
show
small
particl
size
approx
nm
organ
surfac
larger
layer
doubl
hydroxid
ldh
np
mgldh
znldh
mgfeldh
approx
nm
use
hbv
model
viru
hepatomaderiv
cell
viral
replic
reduc
amount
viral
subvir
particl
releas
treat
cell
presenc
aunpsldh
hbv
particl
sequest
within
treat
cell
highest
antivir
hbv
respons
inhibit
hbv
secret
estim
aunpsmgfeldh
carja
et
al
np
test
antivir
activ
hcv
pronouncedli
inhibit
infect
noncytotox
concentr
inhibit
entri
hcv
pseudoparticl
hcvpp
includ
genotyp
effect
hcv
replic
observ
found
stop
hcv
infect
attach
entri
stage
suggest
np
could
use
treatment
patient
chronic
hepat
c
hang
et
al
multifunct
senp
baicalin
folic
acid
surfacemodif
design
target
treatment
hbvinfect
liver
cancer
primarili
target
lysosom
cell
induc
apoptosi
cell
downregul
gener
reactiv
oxygen
speci
ro
express
hbxag
protein
show
superb
abil
inhibit
cancer
cell
migrat
invas
fang
et
al
alumadjuv
hbv
vaccin
consid
effect
measur
prevent
hbv
infect
howev
frostsensit
suspens
therefor
would
desir
use
altern
natur
adjuv
system
strongli
immunogen
allow
reduct
dose
cost
therefor
abdelallah
et
al
subcutan
immun
mice
hbv
surfac
antigen
hbsag
adjuv
cs
sodium
algin
either
alon
combin
alum
estim
rate
seroconvers
serum
hbsag
antibodi
level
compar
control
mice
immun
current
vaccin
formula
unadjuv
hbsag
found
solut
formula
cs
sodium
algin
exhibit
compar
immunogen
respons
alumadjuv
suspens
tripl
adjuv
applic
alum
cs
sodium
algin
result
consider
higher
immunogen
respons
control
compar
tradit
method
vaccin
prepar
nanoscal
materi
show
appropri
biocompat
secur
effect
target
certain
tissu
cell
well
precis
stimul
immun
respons
yang
et
al
hbsagload
trimethyl
cs
tmc
hydroxypropyl
methylcellulos
hypromellos
phthalat
hpmcp
np
particl
size
nm
show
load
capac
load
effici
respect
concentr
antigen
exhibit
improv
acid
stabil
better
protect
entrap
hbsag
gastric
destruct
vitro
wherebi
antigen
show
efficaci
activ
also
load
base
find
could
suggest
tmchpmcp
np
potenti
appli
oral
deliveri
hbsag
vaccin
farhadian
et
al
ndeboko
et
al
studi
inhibit
replic
duck
hepat
b
viru
dhbv
refer
model
human
hbv
infect
peptid
nucleic
acid
pna
conjug
differ
cellpenetr
peptid
cpp
found
pnacpp
conjug
administ
neonat
duckl
reach
liver
inhibit
dhbv
replic
mous
model
conjug
hbv
dna
vaccin
modifi
cs
amelior
cellular
humor
respons
plasmidencod
antigen
plasmid
dna
uptak
wherebi
express
could
also
notabl
increas
use
gene
deliveri
system
cppmodifi
cs
cation
np
biodegrad
np
encapsul
rbv
monophosph
prepar
blend
poli
llactic
acid
homopolym
arabinogalactanpoli
llysin
conjug
effici
intern
cultur
cell
ensur
sustain
releas
drug
could
consid
formul
suitabl
clinic
applic
rbv
therapeut
agent
chronic
hcv
ishihara
et
al
liverspecif
sustain
drug
deliveri
system
prepar
conjug
livertarget
peptid
pegyl
cyclosporin
aencapsul
plga
np
effect
inhibit
viral
replic
vitro
well
hcv
mous
model
jyothi
et
al
adefovir
encapsul
plga
microspher
show
sustain
releas
intramuscular
inject
rat
consider
increas
tmax
auc
mean
resid
time
pronounc
reduct
cmax
observ
suggest
nanoformul
could
use
longterm
treatment
chronic
hepat
b
instead
daili
dose
use
patient
ayoub
et
al
lipid
nanocapsul
surfacefunction
amphiphil
boron
acid
postinsert
semirigid
shell
nanocapsul
found
excel
hcv
entri
inhibitor
prevent
hcv
infect
micromolar
rang
khanal
et
al
phenylboronicacidmodifi
np
potenti
antivir
therapeut
report
previous
also
khanal
et
al
sirnaload
lipid
np
lnp
modifi
hepatocytespecif
ligand
nacetyldgalactosamin
show
pronounc
improv
hepatocytespecif
strong
reduct
toxic
modif
np
peg
practic
elimin
lnpassoci
toxic
without
detect
loss
gene
silenc
activ
hepatocyt
wherebi
singl
inject
lnp
consider
reduc
hbv
genom
dna
antigen
without
sign
toxic
chimer
mice
human
liver
persist
infect
hbv
sato
et
al
ebola
viru
diseas
caus
ebola
virus
ebov
famili
filovirida
member
group
hemorrhag
fever
one
danger
infect
diseas
mortal
rate
ebov
replic
cell
divis
instead
insert
genet
sequenc
dna
host
cell
subsequ
hijack
cellular
process
includ
transcript
translat
thu
host
cell
becom
factori
viral
protein
gebretadik
et
al
murray
found
graphen
sheet
associ
strongli
ebov
matrix
protein
potenti
pharmacolog
target
disrupt
viru
life
cycl
variou
interfac
graphen
disrupt
ctermin
domain
interfac
hexam
crucial
form
ebola
viral
matrix
suggest
graphen
similar
npsbase
solut
use
disinfect
could
notabl
reduc
spread
diseas
prevent
ebola
epidem
gc
et
al
rodriguezperez
et
al
found
mwcnt
function
glycofulleren
consid
potent
inhibitor
ebola
infect
two
mrna
vaccin
base
ebov
envelop
glycoprotein
differ
natur
signal
peptid
improv
glycoprotein
posttransl
transloc
mrna
formul
lnp
facilit
deliveri
vaccin
guinea
pig
induc
ebovspecif
igg
neutral
antibodi
respons
surviv
ebov
infect
meyer
et
al
adjuvantfre
dendrim
np
vaccin
platform
wherein
antigen
encod
encapsul
mrna
replicon
abl
gener
protect
immun
mani
lethal
pathogen
challeng
includ
influenza
toxoplasma
gondii
ebov
form
multipl
antigenexpress
replicon
could
elicit
cell
antibodi
respons
design
chahal
et
al
administr
sirna
encapsul
lnp
abl
target
sudan
ebolaviru
gene
rhesu
monkey
receiv
lethal
dose
viru
result
surviv
reduct
viral
replic
thi
et
al
similar
result
receiv
treatment
ebolavirusmakonainfect
nonhuman
primat
follow
administr
sirna
encapsul
lnp
suggest
therapeut
potenti
nanoformul
combat
lethal
diseas
thi
et
al
incorpor
ebola
dna
vaccin
acid
increas
vaccin
thermost
immunogen
compar
free
vaccin
vaccin
perform
skin
use
microneedl
patch
produc
stronger
immun
respons
intramuscular
administr
yang
et
al
marburg
viru
similarli
ebola
viru
belong
famili
filovirida
caus
sever
often
fatal
hemorrhag
fever
human
nonhuman
primat
high
mortal
rate
viru
transmit
anim
human
contact
bat
monkey
bodili
secret
person
person
although
humantohuman
contamin
rare
sboui
tabbabi
formul
lnp
deliv
sirna
target
antimarburg
viru
nucleoprotein
administ
rhesu
monkey
challeng
lethal
dose
marburg
virusangola
show
excel
therapeut
efficaci
secur
surviv
infect
anim
thi
et
al
protect
lethal
marburg
viru
infect
mediat
lipid
encapsul
sirna
also
observ
virusinfect
guinea
pig
ursicbedoya
et
al
block
infect
tlymphocyt
human
dendrit
cell
ebola
viru
use
glycodendriproteinnp
display
quasiequival
nest
polyval
upon
glycoprotein
platform
consist
glycodendrimer
construct
bear
glycan
diamet
nm
observ
alreadi
picomolar
concentr
ribeiroviana
et
al
newcastl
diseas
contagi
viral
bird
diseas
caus
virul
strain
newcastl
diseas
viru
ndv
caus
substanti
morbid
mortal
event
worldwid
poultri
result
devast
econom
effect
global
domest
poultri
product
ndv
negativesens
singlestrand
rna
viru
capabl
infect
speci
domest
wild
avian
speci
brown
bevin
ndv
transmiss
human
exposur
human
infect
bird
caus
mild
conjunct
influenzalik
symptom
ndv
otherwis
pose
hazard
human
health
abdisa
tagesu
zhao
et
al
design
ndv
f
genecontain
dna
vaccin
encapsul
ag
hollow
np
averag
diamet
nm
follow
intranas
immun
chicken
induc
high
titer
serum
antibodi
notabl
stimul
lymphocyt
prolifer
induc
higher
express
level
suggest
ag
hollow
np
could
use
effici
safe
deliveri
carrier
ndv
dna
vaccin
induc
mucos
immun
intranas
administr
quatern
cs
n
chlorid
csn
ocarboxymethyl
cs
np
load
combin
attenu
live
vaccin
newcastl
diseas
infecti
bronchiti
elicit
immun
respons
chicken
induc
higher
titer
igg
iga
antibodi
notabl
stimul
prolifer
lymphocyt
induc
higher
level
commerci
combin
attenu
live
vaccin
induct
humor
cellular
mucos
immun
respons
protect
anim
infect
highli
virul
ndv
avian
infecti
bronchiti
viru
suggest
cs
deriv
could
use
effici
adjuv
deliveri
carrier
mucos
vaccin
zhao
et
al
quatern
cs
np
load
combin
attenu
live
vaccin
newcastl
diseas
infecti
bronchiti
elicit
immun
respons
chicken
intranas
administr
el
naggar
et
al
design
prepar
mucos
np
polymerbas
inactiv
vaccin
newcastl
diseas
ai
virus
deliv
via
intranas
spray
rout
administr
chicken
enhanc
cellmedi
immun
respons
induc
protect
challeng
abovement
virus
dengu
acut
viral
ill
caus
rna
viru
dengu
viru
denv
member
genu
flaviviru
famili
flavivirida
denv
arthropodeborn
viru
includ
four
differ
serotyp
spread
aed
mosquito
present
featur
may
rang
asymptomat
fever
dread
complic
hemorrhag
fever
shock
consid
major
global
public
health
challeng
tropic
subtrop
nation
hasan
et
al
achiev
durabl
protect
immun
four
serotyp
denv
vaccin
must
induc
balanc
serotypespecif
neutral
antibodi
tetraval
denv
protein
subunit
vaccin
base
recombin
envelop
protein
adsorb
surfac
plga
np
design
particul
induc
higher
neutral
antibodi
titer
compar
solubl
antigen
alon
stimul
balanc
serotypespecif
antibodi
respons
denv
serotyp
compar
solubl
antigen
suggest
vaccin
might
overcom
unbalanc
immun
observ
lead
live
attenu
vaccin
candid
metz
et
al
agnp
show
vitro
antivir
activ
dengu
serotyp
infect
vero
cell
activ
agnp
dengu
vector
aed
aegypti
express
valu
rang
ppm
instar
larva
ppm
pupa
sujitha
et
al
agnp
biosynthes
use
aqueou
extract
bruguiera
cylindrica
leav
significantli
inhibit
product
dengu
viral
envelop
e
protein
vero
cell
downregul
express
dengu
viral
e
gene
found
suitabl
applic
low
dose
reduc
larval
pupal
popul
ae
aegypti
without
detriment
effect
predat
rate
mosquito
predat
carassiu
auratu
murugan
et
al
stabil
agnp
particl
size
nm
zeta
potenti
mv
biosynthes
use
silver
nitrat
carica
papaya
leaf
extract
demonstr
good
bind
affin
dengu
type
viru
nonstructur
protein
renganathan
et
al
treatment
hybrid
consist
aunp
function
domain
iii
envelop
glycoprotein
deriv
serotyp
denv
ediii
result
high
level
antibodi
mediat
serotypespecif
neutral
denv
balbc
mice
found
sizedepend
accord
research
hybrid
concept
could
also
adopt
develop
tetraval
vaccin
four
serotyp
denv
quach
et
al
import
note
good
antivir
activ
dengu
viru
exhibit
also
senp
ramya
et
al
zika
viru
zikv
mosquitoborn
flaviviru
focu
ongo
pandem
public
health
emerg
repres
public
health
threat
due
teratogen
natur
caus
microcephali
babi
born
infect
mother
associ
seriou
neurolog
condit
guillainbarr
syndrom
adult
plourd
bloch
haqu
et
al
propos
strategi
design
effect
safe
vaccin
zikv
includ
tolllik
receptor
base
np
vaccin
develop
biomimet
nanodecoy
nd
trap
zikv
inhibit
zikv
infect
suggest
rao
et
al
nd
compos
gelatin
nanoparticl
core
camouflag
mosquito
medium
host
cell
membran
effect
adsorb
zikv
inhibit
zikv
replic
zikvsuscept
cell
agnp
fabric
use
leaf
extract
cleistanthu
collinu
triangular
pentagon
shape
size
nm
strychno
nuxvomica
spheric
round
shape
size
nm
appli
natur
biolarvicid
agent
vector
control
strategi
ecofriendli
approach
prohibit
zika
chikungunya
dengu
fever
futur
jinu
et
al
insecticid
agnp
prepar
use
suaeda
maritima
found
effect
dengu
vector
ae
aegypti
well
suresh
et
al
bacteri
exopolysaccharideco
zno
np
nanoparticl
show
high
antibiofilm
activ
larvicid
toxic
malaria
zikv
vector
anophel
stephensi
ae
aegypti
mortal
third
instar
mosquito
larva
low
dose
wherebi
midgut
treat
mosquito
larva
presenc
damag
cell
tissu
observ
abinaya
et
al
promis
toxic
repel
activ
zikv
mosquito
vector
show
also
np
prepar
use
extract
argemon
mexicana
cap
poli
styrenesulfon
poli
allylamin
hydrochlorid
murugan
et
al
nanoscal
silic
platelet
modifi
anion
sodium
dodecyl
sulfat
significantli
suppress
plaqueform
abil
japanes
enceph
viru
jev
noncytotox
concentr
block
infect
denv
influenza
viru
also
reduc
lethal
jev
denv
infect
mous
challeng
model
liang
et
al
effici
greensynthes
metal
agnp
aunp
use
biopesticid
ae
aegypti
spread
dengu
viru
culex
quinquefasciatu
stephensi
transmit
zika
viru
present
sever
paper
eg
govindarajan
benelli
lallawmawma
et
al
pavunraj
et
al
ishwarya
et
al
suganya
et
al
rabi
viru
neurotrop
viru
caus
rabi
human
anim
pseudorabi
viru
prv
herpesviru
swine
member
alphaherpesvirina
subfamili
etiolog
agent
aujeszki
diseas
prv
infect
progress
acut
infect
respiratori
epithelium
latent
infect
peripher
nervou
system
wherebi
sporad
reactiv
latenc
transmit
prv
new
host
pomeranz
et
al
au
nanoclust
surfacestabil
histidin
strongli
inhibit
prolifer
prv
found
function
via
blockag
viral
replic
process
rather
process
attach
penetr
releas
observ
mainli
local
nucleu
feng
et
al
go
reduc
go
show
nanosheet
structur
test
dna
viru
prv
rna
viru
porcin
epidem
diarrhea
viru
pedv
suppress
infect
virus
log
reduct
potent
antivir
activ
attribut
uniqu
singlelay
structur
neg
charg
go
reduc
go
wherebi
go
inactiv
virus
structur
destruct
prior
viral
entri
ye
et
al
nonlinear
globular
dendrim
compris
citric
acid
adjuvant
effect
investig
veterinari
rabi
vaccin
show
signific
toxic
effect
cell
ensur
higher
surviv
rate
mice
viru
challeng
vivo
due
adjuvant
effect
dendrim
result
rise
neutral
antibodi
rabi
viru
thu
enhanc
immun
respons
asgari
et
al
agnp
nm
found
prevent
viral
entri
vaccinia
viru
envelop
viru
belong
poxviru
famili
macropinocytosisdepend
mechan
result
inhibit
vaccinia
viru
infect
trefri
wooley
brogli
et
al
test
antivir
activ
aucu
coreshel
np
human
noroviru
norwalk
viruslik
particl
model
viral
system
found
virucid
efficaci
significantli
increas
increas
np
concentr
andor
contact
time
viruslik
particl
np
cui
np
demonstr
high
antivir
activ
nonenvelop
viru
felin
caliciviru
fcv
surrog
human
noroviru
common
etiolog
agent
gastroenter
attribut
cu
ion
follow
gener
ro
subsequ
capsid
protein
oxid
shionoiri
et
al
investig
vitro
antivir
effect
mgo
np
footandmouth
diseas
fmd
extrem
contagi
viral
diseas
clovenhoof
anim
razi
bovin
kidney
cell
line
show
mgo
np
exhibit
virucid
antivir
activ
inhibit
fmd
viru
earli
stage
infect
attach
penetr
penetr
rafiei
et
al
mcgill
et
al
develop
mucos
nanovaccin
postfus
f
g
glycoprotein
bovin
respiratori
syncyti
viru
brsv
encapsul
polyanhydrid
np
test
brsv
infect
use
neonat
calf
model
observ
reduc
patholog
lung
reduc
viral
burden
decreas
viru
shed
compar
unvaccin
control
calv
show
correl
brsvspecif
immun
respons
respiratori
tract
peripher
blood
glutathionecap
nanoclust
show
strong
antivir
activ
pedv
use
model
coronaviru
pronounc
reduct
infect
pedv
three
order
magnitud
noncytotox
concentr
h
postinfect
observ
nanoclust
inhibit
synthesi
viral
negativestrand
rna
viral
bud
posit
regul
gener
interferonstimul
gene
express
proinflamm
cytokin
du
et
al
khandelw
et
al
evalu
antivir
efficaci
agnp
nm
ovin
rinderpest
pest
de
petit
rumin
viru
pprv
prototyp
morbilliviru
caus
diseas
small
rumin
goat
sheep
estim
signific
inhibit
pprv
replic
agnp
experi
use
vero
cell
alreadi
noncytotox
concentr
wherebi
agnp
block
viral
entri
target
cell
due
interact
agnp
virion
surfac
well
virion
core
nanoscal
scienc
nanotechnolog
unambigu
demonstr
great
potenti
provid
novel
improv
solut
nanos
materi
chang
physic
chemic
properti
comparison
bulk
materi
help
improv
innov
varieti
pharmaceut
medic
industri
agricultur
product
thu
nanoformul
antivirot
antivir
vaccin
becom
import
tool
fight
variou
type
virus
due
modifi
bioavail
abil
target
viral
cellular
protein
sustain
releas
drug
also
nanos
materi
found
exhibit
antivir
activ
combin
antivirot
thu
could
provid
remark
medicin
especi
resist
viral
pathogen
howev
spite
signific
benefit
nanomateri
drug
develop
increas
attent
devot
potenti
intrins
toxic
nanomedicin
caus
particl
size
abl
within
side
effect
induc
variou
patholog
process
cellstissu
result
variou
adversehazard
effect
anim
human
